Uracil/tegafur plus oral calcium folinate in advanced breast cancer.

Eduardo Richardet(Instituto Oncológico de Córdoba), Luis Fein(National Cancer Center), G Uranga, Alvarez Am, C.M. Pedraza, M. Bonamasa, E. Mickiewicz(University of Chicago), Mariacarla Ventriglia(University of Naples Federico II), Matteo Bruno(Università Cattolica del Sacro Cuore), Francesca Coppola, S Jovtis, MA CUEVAS(Universidad de Buenos Aires), Guillermo Lerzo, A. Elli, Suarez La

PubMed

July 1, 1999

Cited by 6

Related Papers

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

|New England Journal of Medicine|2004|1.8k

Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer

|New England Journal of Medicine|2007|1.7k

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2018|1.3k

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

|The Lancet|2007|912

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

|Journal of Clinical Oncology|2007|483